Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
News & Press: Industry News

Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out

Wednesday, August 27, 2014   (0 Comments)
Posted by: Megan Jeffrey
Share |
Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out | Puget Sound Business Journal 

more WBBA Calendar

10/23/2014
2014 Fall- From the Laboratory to Leadership

11/13/2014
Pub Night- November

Featured Partners
Culpepper and Associates, Inc.For 30+ years, organizations have relied on Culpepper to help design effective compensation programs

Membership Management Software Powered by YourMembership.com®  ::  Legal/Privacy